GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Evonile Pharma Ltd

Evonile Pharma Q2 FY27 Results: -₹31.8 crore Operating EBITDA amidst transition

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 08:01 PM IST  ·  BSE ID: 0d6bcd3e-c643-4fc1-87be-bdde47acd2e5
View Original BSE Filing (PDF)
💡
In Simple Terms
Evonile Pharma, now owned by ChrysCapital, reported revenue of ₹56.1 crore but an operating loss for Q2 FY27 during its business model transition.
🤖 AI Summary
  • Evonile Pharma reported revenue from operations of ₹56.1 crore for Q2 FY27 (quarter ended September 30, 2026).
  • Operating EBITDA was -₹31.8 crore in Q2 FY27, reflecting one-time transition costs and organizational build-out investment.
  • ChrysCapital acquired a controlling 70.68% stake, transitioning Evonile Pharma from a single-customer model.
  • The company expanded its portfolio by acquiring Minipress XL and entering ophthalmology via an in-licensing agreement.
  • Half-year (H1 FY27) revenue from operations stood at ₹159.9 crore, with a Profit after Tax of -₹45.3 crore.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
₹56.1 crore
Not comparable — limited prior period data.
Operating EBITDA (Q2 FY27)
-₹31.8 crore
Not comparable — limited prior period data.
Revenue from operations (H1 FY27)
₹159.9 crore
Not comparable — limited prior period data.
Profit after Tax (H1 FY27)
-₹45.3 crore
Not comparable — limited prior period data.
ChrysCapital stake
70.68%
🏢 How This Affects the Company
📈
Business Impact
The company transitioned from a single-customer business model to its own distribution network and field force. It expanded its therapeutic areas by acquiring Minipress XL (cardiology) and an ophthalmology in-licensing agreement.
💰
Financial Impact
The company reported an Operating EBITDA of -₹31.8 crore in Q2 FY27 and a Profit after Tax of -₹45.3 crore for H1 FY27, impacted by one-time transition costs and upfront investment.
⚙️
Operational Impact
Evonile Pharma is establishing an entirely new organizational foundation, including an independent distribution and commercial platform, field force, and operating systems.
⚠️
Risk Impact
The significant change in control and business model introduces operational execution risks associated with building new infrastructure and integrating acquisitions.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, including a negative Operating EBITDA of -₹31.8 crore in Q2 FY27 and negative Profit after Tax of -₹45.3 crore for H1 FY27.
🔍
Management Signal
Management is signaling a focus on organizational build-out, establishing an appropriate cost structure, and integrating a strong team to drive future growth after the change in control.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor progress on organizational build-out and cost structure establishment.
Updates on portfolio integration — assess impact of Minipress XL and ophthalmology expansion.
Management statements — look for further details on strategic priorities and growth initiatives.
MEDIUM RISK Significant business model change, negative operating results, and substantial upfront investment present execution risks.
💡 Investor Takeaway
Evonile Pharma, post-ChrysCapital acquisition (70.68% stake), reported Q2 FY27 revenue from operations of ₹56.1 crore and Operating EBITDA of -₹31.8 crore. H1 FY27 Profit after Tax was -₹45.3 crore, reflecting transition costs and investments in new business model.
⚖️ Strengths & Concerns

✅ Positives

  • ChrysCapital's acquisition of a 70.68% controlling stake provides dedicated private equity ownership for future growth.
  • Strategic expansion into cardiology via Minipress XL acquisition and ophthalmology in-licensing diversifies the product portfolio.

⚠️ Concerns

  • Operating EBITDA was -₹31.8 crore in Q2 FY27, reflecting substantial one-time transition costs and upfront investment.
  • Profit after Tax for H1 FY27 stood at -₹45.3 crore, indicating a period of significant losses during the business model transition.
📅 Company Track Record
Evonile Pharma, formerly Novartis India, reported NIL total financial indebtedness for Q1 FY27 (quarter ended June 30, 2026) and FY26 (year ended March 31, 2026) in previous filings. The current filing marks the first results post-change of control by ChrysCapital.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Evonile Pharma's revenue from operations in Q2 FY27?
Evonile Pharma recorded revenue from operations of ₹56.1 crore in Q2 FY27 (quarter ended September 30, 2026).
What was Evonile Pharma's Operating EBITDA for Q2 FY27?
Operating EBITDA for Evonile Pharma stood at -₹31.8 crore in Q2 FY27, impacted by transition costs and organizational investment.
What was Evonile Pharma's financial performance for H1 FY27?
For H1 FY27 (half year ended September 30, 2026), Evonile Pharma's revenue from operations was ₹159.9 crore, and Profit after Tax was -₹45.3 crore.
Who acquired a controlling stake in Evonile Pharma?
ChrysCapital, an Indian private equity investor, acquired a controlling 70.68% stake in Evonile Pharma during Q2 FY27.
Which new therapeutic areas did Evonile Pharma enter?
Evonile Pharma expanded into cardiology with the acquisition of Minipress XL and into ophthalmology through an in-licensing agreement during the quarter.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.